Efficacy of polyvalent human immunoglobulins in an animal model of neuromyelitis optica evoked by intrathecal anti-aquaporin 4 antibodies

International Journal of Molecular Sciences

Volumn 17, Issue 9, 2016, Pages

  Grünewald, Benedikt ^a,b   Bennett, Jeffrey L ^c   Toyka, Klaus V ^b   Sommer, Claudia ^b   Geis, Christian ^a,b  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

Aquaporin 4; Autoantibody; Intrathecal application; IVIg; NMOSD

Indexed keywords

AQUAPORIN 4 ANTIBODY; HUMAN IMMUNOGLOBULIN; AQUAPORIN 4; AUTOANTIBODY; IMMUNOGLOBULIN G;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; BEHAVIOR ASSESSMENT; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; MOTOR PERFORMANCE; MYELOOPTIC NEUROPATHY; NONHUMAN; RAT; SCORING SYSTEM; ANIMAL; DISEASE MODEL; HUMAN; IMMUNOLOGY; INTRASPINAL DRUG ADMINISTRATION; METABOLISM; NEUROMYELITIS OPTICA;

ANIMALS; AQUAPORIN 4; AUTOANTIBODIES; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOGLOBULIN G; INJECTIONS, SPINAL; NEUROMYELITIS OPTICA; RATS;

EID: 84984820401     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms17091407     Document Type: Article

References (29)

1. Wingerchuk, D.M.; Banwell, B.; Bennett, J.L.; Cabre, P.; Carroll, W.; Chitnis, T.; de Seze, J.; Fujihara, K.; Greenberg, B.; Jacob, A.; et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015, 85, 177-189
2. Lennon, V.A.; Wingerchuk, D.M.; Kryzer, T.J.; Pittock, S.J.; Lucchinetti, C.F.; Fujihara, K.; Nakashima, I.; Weinshenker, B.G. A Serum autoantibody marker of neuromyelitis optica: Distinction from multiple sclerosis. Lancet 2004, 364, 2106-2112
3. Lennon, V.A.; Kryzer, T.J.; Pittock, S.J.; Verkman, A.S.; Hinson, S.R. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J. Exp. Med. 2005, 202, 473-477
4. Jasiak-Zatonska, M.; Kalinowska-Lyszczarz, A.; Michalak, S.; Kozubski, W. The immunology of neuromyelitis optica-current knowledge, clinical implications, controversies and future perspectives. Int. J. Mol. Sci. 2016, 17, 273
5. Wingerchuk, D.M.; Lennon, V.A.; Pittock, S.J.; Lucchinetti, C.F.; Weinshenker, B.G. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006, 66, 1485-1489
6. Tan, C.T.; Mao, Z.; Qiu, W.; Hu, X.; Wingerchuk, D.M.; Weinshenker, B.G. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2016, 86, 491-492
7. Ratelade, J.; Asavapanumas, N.; Ritchie, A.M.; Wemlinger, S.; Bennett, J.L.; Verkman, A.S. Involvement of antibody-dependent cell-mediated cytotoxicity in inflammatory demyelination in a mouse model of neuromyelitis optica. Acta Neuropathol. 2013, 126, 699-709
8. Bennett, J.L.; Lam, C.; Kalluri, S.R.; Saikali, P.; Bautista, K.; Dupree, C.; Glogowska, M.; Case, D.; Antel, J.P.; Owens, G.P.; et al. Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann. Neurol. 2009, 66, 617-629
9. Marignier, R.; Nicolle, A.; Watrin, C.; Touret, M.; Cavagna, S.; Varrin-Doyer, M.; Cavillon, G.; Rogemond, V.; Confavreux, C.; Honnorat, J.; et al. Oligodendrocytes are damaged by neuromyelitis optica immunoglobulin G via astrocyte injury. Brain 2010, 133, 2578-2791
10. Geis, C.; Ritter, C.; Ruschil, C.; Weishaupt, A.; Grunewald, B.; Stoll, G.; Holmoy, T.; Misu, T.; Fujihara, K.; Hemmer, B.; et al. The intrinsic pathogenic role of autoantibodies to aquaporin 4 mediating spinal cord disease in a rat passive-transfer model. Exp. Neurol. 2015, 265, 8-21
11. Misu, T.; Höftberger, R.; Fujihara, K.; Wimmer, I.; Takai, Y.; Nishiyama, S.; Nakashima, I.; Konno, H.; Bradl, M.; Garzuly, F.; et al. Presence of six different lesion types suggests diverse mechanisms of tissue injury in neuromyelitis optica. Acta Neuropathol. 2013, 125, 815-827
12. Papadopoulos, M.C.; Bennett, J.L.; Verkman, A.S. Treatment of neuromyelitis optica: State-of-the-art and emerging therapies. Nat. Rev. Neurol. 2014, 10, 493-506
13. Viswanathan, S.; Wong, A.H.; Quek, A.M.; Yuki, N. Intravenous immunoglobulin may reduce relapse frequency in neuromyelitis optica. J. Neuroimmunol. 2015, 282, 92-96
14. Elsone, L.; Panicker, J.; Mutch, K.; Boggild, M.; Appleton, R.; Jacob, A. Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: Experience in 10 patients. Mult. Scler. 2014, 20, 501-504
15. Ratelade, J.; Smith, A.J.; Verkman, A.S. Human immunoglobulin G reduces the pathogenicity of aquaporin-4 autoantibodies in neuromyelitis optica. Exp. Neurol. 2014, 255, 145-153
16. Gold, R.; Stangel, M.; Dalakas, M.C. Drug Insight: The use of intravenous immunoglobulin in neurology-Therapeutic considerations and practical issues. Nat. Clin. Pract. Neurol. 2007, 3, 36-44
17. Hughes, R.A.; Swan, A.V.; van Doorn, P.A. Intravenous immunoglobulin for Guillain-Barre syndrome. Cochrane Database Syst. Rev. 2014
18. Magraner, M.J.; Coret, F.; Casanova, B. The effect of intravenous immunoglobulin on neuromyelitis optica. Neurologia 2013, 28, 65-72
19. Bichuetti, D.; Boulos, F.; Shinosaki, J.; Souza, N.; Oliveira, E.; Gabbai, A. Treatment of Neuromyelitis Optica with Intravenous Immunoglobulin: Report of 8 Patients. Neurology 2012, 78 (Suppl. 1), P04141
20. Yu, Z.; Lennon, V.A. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N. Engl. J. Med. 1999, 340, 227-228
21. Dalakas, M.C. Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: Present status and practical therapeutic guidelines. Muscle Nerve 1999, 22, 1479-1497
22. Buchwald, B.; Ahangari, R.; Weishaupt, A.; Toyka, K.V. Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barre syndrome. Ann. Neurol. 2002, 51, 673-680
23. Buchwald, B.; Ahangari, R.; Weishaupt, A.; Toyka, K.V. Presynaptic effects of immunoglobulin G from patients with Lambert-Eaton myasthenic syndrome: Their neutralization by intravenous immunoglobulins. Muscle Nerve 2005, 31, 487-494
24. Kilkenny, C.; Browne, W.J.; Cuthill, I.C.; Emerson, M.; Altman, D.G. Improving bioscience research reporting: The arrive guidelines for reporting animal research. PLoS Biol. 2010, 8, e1000412
25. Geis, C.; Weishaupt, A.; Hallermann, S.; Grunewald, B.; Wessig, C.; Wultsch, T.; Reif, A.; Byts, N.; Beck, M.; Jablonka, S.; et al. Stiff person syndrome-associated autoantibodies to amphiphysin mediate reduced GABAergic inhibition. Brain 2010, 133, 3166-3180
26. Gabriel, C.M.; Gregson, N.A.; Redford, E.J.; Davies, M.; Smith, K.J.; Hughes, R.A. Human immunoglobulin ameliorates rat experimental autoimmune neuritis. Brain 1997, 120, 1533-1540
27. Enders, U.; Toyka, K.V.; Hartung, H.P.; Gold, R. Failure of intravenous immunoglobulin (IVIg) therapy in experimental autoimmune neuritis (EAN) of the Lewis rat. J. Neuroimmunol. 1997, 76, 112-116
28. Sommer, C.; Weishaupt, A.; Brinkhoff, J.; Biko, L.; Wessig, C.; Gold, R.; Toyka, K.V. Paraneoplastic stiff-person syndrome: Passive transfer to rats by means of IgG antibodies to amphiphysin. Lancet 2005, 365, 1406-1411
29. Linker, R.A.; Maurer, M.; Gaupp, S.; Martini, R.; Holtmann, B.; Giess, R.; Rieckmann, P.; Lassmann, H.; Toyka, K.V.; Sendtner, M.; et al. CNTF is a major protective factor in demyelinating CNS disease: A neurotrophic cytokine as modulator in neuroinflammation. Nat. Med. 2002, 8, 620-624